Approval · Notice of Compliance 14765 · 2013
VIREAD: Notice of Compliance 14765
Issued September 26, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14765
- Date
- September 26, 2013
- Company
- Gilead Sciences Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Expanded indication to include patients with lamivudine resistant hepatitis b virus
- Therapeutic class
- Antiretroviral agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VIREAD | Not yet assigned | — |
Medicinal ingredients
- TENOFOVIR DISOPROXIL FUMARATE 300 MG per TAB